Insmed (INSM) investor relations material

Commercial performance and launch updates

• BRINSUPRI launch is tracking as one of the top 25 in industry history, with expectations to exceed $1 billion in first-year sales and over 5,000 prescribers engaged.

• Market access and physician feedback are strong, with about 1/3 of patients experiencing symptomatic benefit within 2–4 weeks.

• Discontinuation rates are in line with expectations, mainly occurring early due to adverse events or loss of follow-up, with ongoing efforts to reengage patients.

• Over 80% of patients opt into the inLighten support program, enabling high-touch engagement and education to drive persistence.

• Sales force strategy focuses on deepening engagement with high-volume prescribers and broadening reach among community physicians, targeting a growing addressable market of 500,000+ patients.

Strategic growth and future opportunities

• A second wave of growth is anticipated from targeting comorbid COPD and asthma patients with bronchiectasis, potentially expanding the market significantly by 2027–2028.

• Symphony TRX data is closely tracked as a proxy for launch progress, with guidance anchored on new patient adds and revenue, avoiding excessive data points to reduce confusion.

• Japanese launches for both BRINSUPRI and ARIKAYCE are planned for next year, with expectations of strong uptake due to higher efficacy in Asian populations.

• ARIKAYCE is positioned for first-line launch in the U.S. and Japan, with a strong target product profile and anticipated early adoption.

Pipeline and clinical development

• TPIP has four phase III trials underway, with significant Q3 data updates expected, focusing on long-term efficacy, safety, and dose escalation.

• TPIP demonstrates superior reduction in pulmonary vascular resistance compared to competitors, targeting multiple indications and expected to be a major commercial driver.

• Early-stage pipeline includes next-generation DPP1 inhibitors, de-immunized therapeutic proteins, and gene therapies for DMD and ALS, with clinical updates expected in 2026–2027.

• The company anticipates one to two new INDs annually, leveraging past acquisitions and internal R&D platforms.